TOX3 rs4784770: Understanding Breast Cancer Risk Associations
The rs4784770 variant is a common genetic marker located in the TOX3 gene region on chromosome 16. It has been identified in large-scale genome-wide association studies as being linked to an increased susceptibility to estrogen receptor-positive breast cancer.
What each genotype means
Baseline breast cancer risk
This genotype represents the common version of the TOX3 variant. Research indicates that individuals with this genotype do not carry the specific risk allele associated with increased susceptibility to estrogen receptor-positive breast cancer at this locus.
Carried by approximately 50-60% of individuals of European ancestry.
Slightly increased risk profile
This genotype includes one copy of the risk-associated allele. Studies suggest that carriers of this allele may have a statistically higher susceptibility to estrogen receptor-positive breast cancer compared to those without it, though the individual risk remains influenced by many other genetic and environmental factors.
Carried by roughly 35-40% of individuals of European ancestry.
Elevated breast cancer risk
This genotype includes two copies of the risk-associated allele. Population studies associate this genotype with a higher statistical risk for estrogen receptor-positive breast cancer, though this is a common variant with low individual penetrance and should not be interpreted as a diagnostic indicator.
Carried by roughly 5-10% of individuals of European ancestry.
What is rs4784770?
The rs4784770 variant is a single nucleotide polymorphism (SNP) located within the 16q12 genomic locus. In genetics, a SNP represents a variation at a single position in a DNA sequence among individuals. This specific variant is situated in an intergenic region near the TOX3 gene. Because it is located in a non-coding area of the genome, it does not change the protein sequence of the gene itself. Instead, researchers investigate such variants to see if they influence how nearby genes are regulated or expressed. The rs4784770 marker is frequently studied alongside other variants in the 16q12 region to better understand the complex genetic architecture that may contribute to breast cancer risk. It is important to note that being a carrier of a specific allele at this position does not mean an individual will develop a disease; rather, it is a statistical association observed in large population studies.
The Role of the TOX3 Gene
The TOX3 gene, also known as TOX High Mobility Group Box Family Member 3, is located on chromosome 16. While the exact biological function of the TOX3 protein is still being characterized, it is believed to play a role in chromatin remodeling and transcriptional regulation. In the context of breast cancer research, the 16q12 locus containing TOX3 has been a major focus of investigation. Studies suggest that genetic variation in this region may influence the expression levels of TOX3 or neighboring genes, potentially affecting cellular processes related to breast tissue development or maintenance. Because breast cancer is a heterogeneous disease, researchers are particularly interested in how these regulatory changes might specifically influence the development of estrogen receptor-positive (ER+) breast cancer. Ongoing research continues to explore how these non-coding variants interact with the cellular environment to modulate risk.
Evidence and Statistical Associations
The association between the 16q12 locus and breast cancer is supported by multiple genome-wide association studies (GWAS). These studies compare the frequency of genetic variants in large groups of individuals with breast cancer against those without the condition to identify statistical correlations. The evidence for rs4784770 is considered limited in terms of clinical utility, meaning it is not currently used as a standalone diagnostic tool. While the statistical signal is robust in large cohorts, the individual effect size of this variant is relatively small. Furthermore, the association is primarily observed in estrogen receptor-positive breast cancer cases. It is crucial to understand that these findings are based on population-level data and do not provide a definitive prediction for any single person. Genetic risk is only one component of breast cancer susceptibility, which also involves environmental factors, lifestyle, and other genetic influences.
Population Frequency
The rs4784770 variant is relatively common in human populations, particularly those of European ancestry. Research indicates that the minor allele frequency for this SNP typically ranges between 0.25 and 0.30 in these groups. Because allele frequencies can vary significantly across different global populations, the portability of these genetic associations to non-European ancestries is an active area of study. When a causal variant is common, its ability to predict risk across diverse groups can be reduced, highlighting the importance of conducting large-scale genetic studies in diverse populations to ensure findings are broadly applicable. Understanding these frequency differences helps scientists refine their models of disease risk and ensures that genetic research remains inclusive and accurate for all individuals.
What This Information Means for You
If you have encountered this variant in a genetic report, it is important to view it within the context of your overall health. This SNP is a research-grade marker, not a clinical diagnostic test. It does not provide a medical diagnosis or a definitive assessment of your personal risk for breast cancer. Genetic associations are complex and often involve the interplay of many different genes and environmental factors. You should never use this information to make decisions about medical screenings, treatments, or lifestyle changes without consulting a healthcare professional. If you have concerns about your family history or personal risk of breast cancer, the most effective step is to speak with a doctor or a certified genetic counselor. They can provide personalized guidance based on your complete medical history, clinical risk factors, and established screening guidelines.
How common is this variant?
The minor allele frequency for rs4784770 is approximately 0.25 to 0.30 in European ancestries, making it a common variant in these populations.
Frequently asked questions
Does having the rs4784770 variant mean I will get breast cancer?
No. This variant is only associated with a small, statistical increase in risk for a specific subtype of breast cancer at a population level. It is not a diagnostic test and cannot predict whether an individual will develop the disease.
Should I change my breast cancer screening schedule based on this SNP?
No. You should not change your medical care or screening schedule based on this genetic variant. Always follow the screening guidelines recommended by your healthcare provider based on your personal and family medical history.
Is this variant related to BRCA1 or BRCA2 mutations?
The rs4784770 variant is distinct from the high-risk mutations found in the BRCA1 and BRCA2 genes. While both are studied in the context of breast cancer, they represent very different types of genetic risk.
Where can I find more information about my personal breast cancer risk?
The best way to assess your personal risk is to consult with a doctor or a certified genetic counselor. They can evaluate your family history, lifestyle factors, and clinical data to provide appropriate medical advice.
Sources & further reading
Educational information only, last refreshed 9/19/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs4784770?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in TOX3
This locus variant in TOX3 confers a moderately increased risk of estrogen receptor-positive breast cancer.
Intronic susceptibility locus strongly associated with altered TOX3 enhancer activity and increased risk of estrogen receptor-positive breast cancer.
Variant in a non-coding regulatory element modulating FOXA1 binding and chromatin affinity, significantly influencing TOX3 expression and predisposition to breast cancer.